Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATOther Gross PP&E Adjustments
Ratios

KalVista Pharmaceuticals (KALV) EBIAT (2016 - 2025)

KalVista Pharmaceuticals' EBIAT history spans 11 years, with the latest figure at -$52.2 million for Q2 2025.

  • For Q2 2025, EBIAT fell 16.97% year-over-year to -$52.2 million; the TTM value through Apr 2025 reached -$179.6 million, down 41.8%, while the annual FY2025 figure was -$183.4 million, 44.85% down from the prior year.
  • EBIAT for Q2 2025 was -$52.2 million at KalVista Pharmaceuticals, down from -$42.3 million in the prior quarter.
  • Across five years, EBIAT topped out at -$10.0 million in Q1 2021 and bottomed at -$52.2 million in Q2 2025.
  • The 4-year median for EBIAT is -$34.7 million (2024), against an average of -$34.0 million.
  • The largest annual shift saw EBIAT decreased 8.15% in 2021 before it plummeted 59.75% in 2024.
  • A 4-year view of EBIAT shows it stood at -$10.0 million in 2021, then crashed by 175.18% to -$27.6 million in 2023, then plummeted by 52.87% to -$42.3 million in 2024, then fell by 23.56% to -$52.2 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's EBIAT are -$52.2 million (Q2 2025), -$42.3 million (Q4 2024), and -$40.4 million (Q3 2024).